Sign in

Private company

Kaleido Biosciences, Inc.

American biological products company, incorporated in Delaware1

In its 2022 annual report the company says: “We are a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the microbiome to treat disease and improve human health. Our product candidates are Microbiome Metabolic Therapies which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. We have an industrialized approach to the discovery and development of MMTs, and our initial MMTs are targeted glycans.”34 It is headquartered in Bedford, Massachusetts.1

Last updated Oct 21, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersBedford, Massachusetts1
  • Incorporated inDE2
  • Business address18 Crosby Drive, Bedford, Ma 017302
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-7940.9%Operating margin3
-8178.3%Net margin3
13.2%Revenue growth, 20213
-851.2%Return on equity3
0.52×Debt to equity3
-$78.2MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development96¢$67.8M
  • Interest4¢$2.8M

Out of $1.1M in revenue.3 The company lost money this year.

Financial statements

Revenue3$1.1M in 2021+13% since 2020
0$500.0K$1.0M$1.5M2020: $975.0K$975.0K20202021: $1.1M$1.1M2021+13%
Operating income453-$87.7M in 2021+44% since 2018
-$100.0M-$75.0M-$50.0M-$25.0M02018: -$60.7M-$60.7M20182019: -$86.7M-$86.7M2019+43%2020: -$78.9M-$78.9M2020−9%2021: -$87.7M-$87.7M2021+11%
Net income453-$90.3M in 2021+46% since 2018
-$100.0M-$75.0M-$50.0M-$25.0M02018: -$61.7M-$61.7M20182019: -$86.3M-$86.3M2019+40%2020: -$81.6M-$81.6M2020−5%2021: -$90.3M-$90.3M2021+11%
Fiscal year20172018201920202021
Revenue$975.0K3$1.1M3
Research and development$42.1M4$64.2M5$56.0M3$67.8M3
Operating expenses$88.8M3
Operating income-$60.7M4-$86.7M5-$78.9M3-$87.7M3
Interest$1.0M4$977.0K5$2.8M3$2.8M3
Income tax$04$05
Net income-$61.7M4-$86.3M5-$81.6M3-$90.3M3

Compare Kaleido Biosciences, Inc. with another company

Corporate structure

Kaleido Biosciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Kaleido Biosciences, Inc.

  • FMR LLC Filed SC 13G/A on Kaleido Biosciences, Inc., latest May 10, 2022 (2 filings since Feb 9, 2022)
  • Kaleido Biosciences, Inc. Bedford, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Kaleido Biosciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$11.1M3 Dec 31, 2021$12.0M3 Dec 31, 2020−6.9%
Accumulated depreciation$5.5M3 Dec 31, 2021$3.5M3 Dec 31, 2020+56.6%
Property and equipment, net$5.7M3 Dec 31, 2021$8.5M3 Dec 31, 2020−33.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$38.5M3 Dec 31, 2021$46.2M3 Dec 31, 2020−16.8%

Leadership

Who has led Kaleido Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Daniel L. Menichella2020–2022

Chair

  1. Michael W. Bonney2019

Chief financial officer

  1. William E. Duke2019–2022

Chief operating officer

  1. Jerald Korn2022
20202025
Board members and other officers (19)

Timeline

  1. Apr 8, 20228-K Listing notice or transfer; Executive or director change; Other events27
  2. Mar 17, 20228-K Executive or director change28
  3. Mar 9, 20228-K Executive or director change29
  4. Jan 28, 20228-K Other events30
  5. Nov 1, 20218-K Results of operations31
  6. Oct 5, 20218-K Other events32
  7. Oct 19, 2020New chief executive Daniel L. Menichella becomes CEO6

Calendar

When it reported results

  1. Nov 1, 2021Reported quarterly or annual results31

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

27 filings to the SEC since October 2021: 1 annual reports, 1 quarterly reports, 6 major events, 9 insider forms, 2 large holders, 8 other. The latest 20:

  1. May 10, 2022SC 13G/A EDGAR
  2. May 6, 202215-12B EDGAR
  3. Apr 29, 2022EFFECT EDGAR
  4. Apr 25, 2022S-8 POS EDGAR
  5. Apr 25, 2022S-8 POS EDGAR
  6. Apr 25, 2022S-8 POS EDGAR
  7. Apr 25, 2022POS AM EDGAR
  8. Apr 18, 202225 EDGAR
  9. Apr 8, 20228-K EDGAR
  10. Apr 1, 2022NT 10-K EDGAR
  11. Apr 1, 202210-K EDGAR
  12. Mar 17, 20228-K EDGAR
  13. Mar 9, 20228-K EDGAR
  14. Mar 2, 20224 FORM 4 SUBMISSION EDGAR
  15. Mar 2, 20224 FORM 4 SUBMISSION EDGAR
  16. Feb 9, 2022SC 13G/A EDGAR
  17. Jan 28, 20228-K EDGAR
  18. Jan 18, 20224 FORM 4 SUBMISSION EDGAR
  19. Jan 18, 20224 FORM 4 SUBMISSION EDGAR
  20. Jan 18, 20224 FORM 4 SUBMISSION EDGAR

The 27 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • FMR LLCSC 13G/A, 2 filings Feb 9, 2022 to May 10, 202233

SEC filer profile

How Kaleido Biosciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARKaleido Biosciences, Inc.1
  • CIK0001751299
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • Business address18 Crosby Drive, Bedford, MA 017301
  • Phone617-674-90001
  • Shares outstanding42,622,559 as of Mar 31, 20223
  • Public float$142.3M as of Jun 30, 20213
  • On EDGAR sinceSep 25, 20181
  • Filings203 in all: 4 (61), 8-K (44), 3 (22), 10-Q (9), CORRESP (6), UPLOAD (6), EFFECT (5), 424B5 (4)1
    All 34 form types

    SEC STAFF LETTER (4), 10-K (3), S-8 (3), S-8 POS (3), SC 13G/A (3), DEF 14A (2), DEFA14A (2), DRS/A (2), DRSLTR (2), POS AM (2), S-1/A (2), S-3 (2), SC 13D/A (2), SC 13G (2), 15-12B (1), 25 (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), CT ORDER (1), DRS (1), NT 10-K (1), POS EX (1), S-1 (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Apr 1, 2022
    Quarterly report (10-Q) Nov 1, 2021
    Proxy statement (DEF 14A) May 5, 2021
    Latest 8-K (8-K) Apr 8, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34